Precision Medicine and Obesity

Maria Daniela Hurtado A, Andres Acosta, Maria Daniela Hurtado A, Andres Acosta

Abstract

The highly variable response to obesity therapies justifies the search for treatment strategies that are best suited to individual patients to enhance their effectiveness and tolerability via precision medicine. Precision medicine development in recent years has been driven by the emergence of powerful methods to characterize patients ("omic" assays). Current available information has revealed that there are numerous intermediary processes that contribute to obesity and have provided a framework for partially comprehending the mechanisms behind the heterogeneity of obesity and its clinical consequences. Some of these processes have or are currently being targeted to individualize obesity therapy with some success.

Keywords: Nutrigenomics; Obesity; Personalized nutrition; Phenotype; Precision medicine.

Conflict of interest statement

Disclosure M.D. Hurtado A has nothing to disclose. A. Acosta is a stockholder in Gila Therapeutics and Phenomix Sciences; and serves as a consultant for Rhythm Pharmaceuticals and General Mills.

Copyright © 2020 Elsevier Inc. All rights reserved.

References

    1. Collaborators TGO. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine. 2017;377(1):13–27.
    1. Organization WH. 2016.
    1. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. Jama. 2016;315(21):2284–2291.
    1. Waters HaGM. America’s Obesity Crisis: the Health and Economic Costs of excess weight. The Milken Institute; October 26, 2018 2018.
    1. Collins FS, Varmus H. A New Initiative on Precision Medicine. The New England journal of medicine. 2015.
    1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51s–209s.
    1. Blüher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Current Opinion in Lipidology. 2010;21(1):38–43.
    1. Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. British Medical Journal (Clinical research ed). 1984;288(6428):1401–1404.
    1. Pischon T, Boeing H, Hoffmann K, et al. General and Abdominal Adiposity and Risk of Death in Europe. New England Journal of Medicine. 2008;359(20):2105–2120.
    1. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. International Journal of Obesity. 2009;33(3):289–295.
    1. Kuk JL, Ardern CI, Church TS, et al. Edmonton Obesity Staging System: association with weight history and mortality risk. Appl Physiol Nutr Metab. 2011;36(4):570–576.
    1. Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. The lancet Diabetes & endocrinology. 2018;6(3):223–236.
    1. Saeed S, Arslan M, Froguel P. Genetics of Obesity in Consanguineous Populations: Toward Precision Medicine and the Discovery of Novel Obesity Genes. Obesity. 2018;26(3):474–484.
    1. Kaur Y, de Souza RJ, Gibson WT, Meyre D. A systematic review of genetic syndromes with obesity. Obes Rev. 2017;18(6):603–634.
    1. Schousboe K, Visscher PM, Erbas B, et al. Twin study of genetic and environmental influences on adult body size, shape, and composition. Int J Obes Relat Metab Disord. 2004;28(1):39–48.
    1. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. The New England journal of medicine. 1990;322(21):1483–1487.
    1. Yang J, Bakshi A, Zhu Z, et al. Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat Genet. 2015;47(10):1114–1120.
    1. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206.
    1. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093–1103.
    1. Collet TH, Dubern B, Mokrosinski J, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321–1329.
    1. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008;105(20):7257–7262.
    1. Marigorta UM, Gibson G. A simulation study of gene-by-environment interactions in GWAS implies ample hidden effects. Frontiers in Genetics. 2014;5(225).
    1. Hollands GJ, French DP, Griffin SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. Bmj. 2016;352:i1102.
    1. Meisel SF, Beeken RJ, van Jaarsveld CHM, Wardle J. Genetic susceptibility testing and readiness to control weight: Results from a randomized controlled trial. Obesity. 2015;23(2):305–312.
    1. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33 Suppl:245–254.
    1. Rohde K, Keller M, la Cour Poulsen L, Blüher M, Kovacs P, Böttcher Y. Genetics and epigenetics in obesity. Metabolism. 2019;92:37–50.
    1. Fabre O, Ingerslev LR, Garde C, Donkin I, Simar D, Barrès R. Exercise training alters the genomic response to acute exercise in human adipose tissue. Epigenomics. 2018;10(8):1033–1050.
    1. Kirchner H, Nylen C, Laber S, et al. Altered promoter methylation of PDK4, IL1 B, IL6, and TNF after Roux-en Y gastric bypass. Surgery for Obesity and Related Diseases. 2014;10(4):671–678.
    1. Rangel-Huerta OD, Pastor-Villaescusa B, Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. 2019;15(6):93–93.
    1. Cirulli ET, Guo L, Leon Swisher C, et al. Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. Cell Metab. 2019;29(2):488–500.e482.
    1. Stroeve JH, Saccenti E, Bouwman J, et al. Weight loss predictability by plasma metabolic signatures in adults with obesity and morbid obesity of the DiOGenes study. Obesity (Silver Spring). 2016;24(2):379–388.
    1. Geidenstam N, Magnusson M, Danielsson APH, et al. Amino Acid Signatures to Evaluate the Beneficial Effects of Weight Loss. Int J Endocrinol. 2017;2017:6490473.
    1. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–848.
    1. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–15723.
    1. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science (New York, NY). 2013;341(6150):1241214.
    1. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772.
    1. Bauer PV, Hamr SC, Duca FA. Regulation of energy balance by a gut–brain axis and involvement of the gut microbiota. Cellular and Molecular Life Sciences. 2016;73(4):737–755.
    1. Dao MC, Everard A, Aron-Wisnewsky J, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65(3):426–436.
    1. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227.
    1. Schnorr SL, Candela M, Rampelli S, et al. Gut microbiome of the Hadza hunter-gatherers. Nat Commun. 2014;5:3654.
    1. Palleja A, Kashani A, Allin KH, et al. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Medicine. 2016;8(1):67.
    1. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–188.
    1. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond). 2008;32(11):1720–1724.
    1. Kalliomäki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008;87(3):534–538.
    1. Sivamaruthi BS, Kesika P, Suganthy N, Chaiyasut C. A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements. Biomed Res Int. 2019;2019:3291367.
    1. Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes. Diabetes Care. 2015;38(1):159–165.
    1. Verhaegen AA, Van Gaal LF. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. J Endocrinol Invest. 2017;40(11):1165–1174.
    1. Zhang JP, Lencz T, Zhang RX, et al. Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophr Bull. 2016;42(6):1418–1437.
    1. Secher A, Bukh J, Bock C, et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol. 2009;24(4):199–203.
    1. Bai X, Xu C, Wen D, et al. Polymorphisms of peroxisome proliferator-activated receptor gamma (PPARgamma) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients. Psychopharmacology (Berl). 2018;235(9):2665–2673.
    1. Molnar A, Kovesdi A, Szucs N, et al. Polymorphisms of the GR and HSD11B1 genes influence body mass index and weight gain during hormone replacement treatment in patients with Addison’s disease. Clin Endocrinol (Oxf). 2016;85(2):180–188.
    1. Kang ES, Cha BS, Kim HJ, et al. The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care. 2006;29(6):1320–1324.
    1. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. The New England journal of medicine. 2017;376(3):254–266.
    1. Li QS, Lenhard JM, Zhan Y, et al. A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus. Pharmacogenet Genomics. 2016;26(2):53–65.
    1. Jensterle M, Pirs B, Goricar K, Dolzan V, Janez A. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol. 2015;71(7):817–824.
    1. Fenech M, El-Sohemy A, Cahill L, et al. Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. J Nutrigenet Nutrigenomics. 2011;4(2):69–89.
    1. Arkadianos I, Valdes AM, Marinos E, Florou A, Gill RD, Grimaldi KA. Improved weight management using genetic information to personalize a calorie controlled diet. Nutr J. 2007;6:29.
    1. Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial. JAMA. 2018;319(7):667–679.
    1. Camilleri M, Acosta A. Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. Gastrointestinal endoscopy. 2016;83(1):48–56.
    1. Acosta A, Camilleri M, Shin A, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology. 2015;148(3):537–546.e534.
    1. Acosta A, Camilleri M, Burton D. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Vol 32015.
    1. Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890–899.
    1. Ramos-Lopez O, Milagro FI, Allayee H, et al. Guide for Current Nutrigenetic, Nutrigenomic, and Nutriepigenetic Approaches for Precision Nutrition Involving the Prevention and Management of Chronic Diseases Associated with Obesity. Lifestyle Genomics. 2017;10(1–2):43–62.
    1. Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 2017;25(1):43–56.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться